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CD36 is a cell surface glycoprotein composed of a sin-
gle polypeptide chain, which interacts with throm-
bospondin, collagens type I and IV, oxidized low density
lipoprotein, fatty acids, anionic phospholipids, and
erythrocytes parasitized with Plasmodium falciparum.
Its expression is restricted to a few cell types, including
monocyte/macrophages. In these cells, CD36 is involved
in phagocytosis of apoptotic cells, and foam cell forma-
tion by uptake of oxidized low density lipoprotein. To
study the molecular mechanisms that control the tran-
scription of the CD36 gene in monocytic cells we have
isolated and analyzed the CD36 promoter. Transient ex-
pression experiments of 5*-deletion fragments of the
CD36 promoter coupled to luciferase demonstrated that
as few as 158 base pairs upstream from the transcription
initiation site were sufficient to direct the monocyte-
specific transcription of the reporter gene. Within the
above region, the fragment spanning nucleotides 2158
to 290 was required for optimal transcription in mono-
cytic cells. Biochemical analysis of the region 2158/290
revealed a binding site for transcription factors of the
polyomavirus enhancer-binding protein 2/core-binding
factor (PEBP2/CBF) family at position 2103. Disruption
of the PEBP2/CBF site markedly diminished the CD36
promoter activity, indicating an essential role of the
PEBP2/CBF factors in the constitutive transcription of
the CD36 gene. The involvement of members of the
PEBP2/CBF family in chromosome translocations asso-
ciated with acute myeloid leukemia, and in the tran-
scriptional regulation of the myeloid-specific genes en-
coding for myeloperoxidase, elastase, and the colony-
stimulating factor receptor, highlights the relevance of
the regulation of the CD36 gene promoter in monocytic
cells by members of the PEBP2/CBF family.
CD36 is a plasma membrane glycoprotein constituted by a
single 88-kDa polypeptide chain (Greenwalt et al., 1992). It is a
member of a family of proteins, which includes CLA-1 and
LIMPII (Vega et al., 1991; Calvo and Vega, 1993; Calvo et al.
1995). CD36 binds to a large variety of ligands: throm-
bospondin (Ash et al., 1987; Silverstein et al., 1992), collagens
type I (Tandon et al., 1989) and IV (Ash et al., 1993), fatty acids
(Abumrad et al., 1993), oxidized low density lipoprotein (Ende-
mann et al., 1993), anionic phospholipids (Rigotti et al., 1995),
and Plasmodium falciparum-infected erythrocytes (Barnwell et
al., 1985; Oquendo et al., 1989). CD36 is present on monocyte/
macrophages, platelets, microvascular endothelium, adipo-
cytes, mammary epithelial cells, and erythroblasts (Barnwell et
al., 1985; Oquendo et al., 1989; Kieffer et al., 1989; Greenwalt
et al., 1992; van Schravendijk et al., 1992; Swerlick et al., 1992;
Abumrad et al., 1993; Greenwalt et al., 1995).
On the basis of its broad ligand-binding specificity, CD36 is
considered as a scavenger receptor (Endemann et al. 1993;
Acton et al., 1994; Nicholson et al., 1995). Scavenger receptors
are primarily expressed on macrophages and participate in cell
clearance of damaged cellular components and cells and foreign
substances such as chemical compounds and pathogens
(Krieger and Herz, 1994). In this respect, CD36 expressed in
monocyte/macrophage cells cooperates with the avb3 vitronec-
tin receptor in the recognition and subsequent phagocytic
clearance of apoptotic cells (including neutrophils, T lympho-
cytes, and eosinophils) migrated to inflamed areas (Savill et al.,
1992; Ren et al., 1995). In addition, CD36 expressed on macro-
phages infiltrated in damaged endothelium participates in the
macrophage uptake of locally formed oxidized low density li-
poprotein, thus contributing to foam cell formation and ather-
osclerosis development (Endemann et al., 1993; Nicholson et
al., 1995).
In vivo regulation of CD36 expression in monocytes may be a
complex process resulting from the coordinated interplay be-
tween multiple soluble factors and cell surface adhesion mole-
cules. Thus, CD36 expression is dramatically increased on
monocytes upon their interaction with activated endothelium
and by treatment of monocytes with macrophage colony-stim-
ulating factor or interleukin-4 (Huh et al., 1995). Moreover,
CD36 expression varies in some myeloproliferative disorders
(Clezardin et al., 1985) and is induced during the differentia-
tion of promonocytes to monocytes and macrophages (Edelman
et al., 1986). Up-regulation of CD36 may increase macrophage
clearance of apoptotic cells and facilitate monocyte migration
through the endothelial barrier, enhancing oxidized low den-
sity lipoprotein uptake and monocyte-extracellular matrix in-
teractions. On the contrary, treatment with lipopolysaccharide
or g-interferon results in down-regulation of CD36 mRNA (Huh
et al., 1995).
Despite the existence of a substantial amount of data regard-
ing CD36 expression, little information is available on the
mechanisms underlying its transcriptional regulation. We have
recently delineated the structural organization of the CD36
gene, which revealed the presence of a TATA box located 28
base pairs upstream from the transcription initiation site
(Armesilla and Vega, 1994). To define the CD36 gene regions,
and to identify the transcription factors important for the ex-
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pression of CD36 in monocyte/macrophage cells, we have iso-
lated and characterized the 59-flanking region of the human
CD36 gene. Our data demonstrate that the transcription of the
CD36 gene in monocytic cell lines is mainly controlled by its
proximal promoter region and that transcription factors be-
longing to the polyomavirus enhancer-binding protein 2/core-
binding factor (PEBP2/CBF)1 family play a major role in the
transcriptional regulation of the CD36 gene.
EXPERIMENTAL PROCEDURES
Cell Culture and Transient Transfections—The cell lines used in this
study, U937, Mono Mac 6, and THP-1 (monocytic), Jurkat (T cell leu-
kemia), K562 (erytholeukemic cell line), JY (B lymphoblastoid cell line),
and HeLa (epitheloid carcinoma) were cultured in RPMI 1640 medium
supplemented with 10% fetal calf serum, and 2 mM L-glutamine. Pe-
ripheral blood monocytes were isolated from blood obtained from
healthy volunteer donors by centrifugation on Ficoll-Hypaque and sub-
sequent adhesion to tissue culture dishes.
U937, Mono Mac 6, Jurkat, and K562 cells were transfected by
electroporation. 20 3 106 U937 or Mono Mac 6 cells were electroporated
in 500 ml of RPMI 1640 medium. Electroporation parameters were set
at 2950 microfarads, 100 V, and a resistance of 186 ohms. 20 3 106
K562 cells were electroporated like U937 cells with the electric param-
eters set up to 400 V, 600 microfarads, and 13 ohms. Jurkat cells were
electroporated in 250 ml of OPTI-MEMmedium (Life Technologies, Inc.)
supplemented with 10% fetal calf serum with the following electropo-
ration parameters: 1700 microfarads, 126 V, and a resistance of 72
ohms. For all electroporation experiments, the cells were incubated a
4 °C for 20 min prior to and after the electric shock. For each electro-
poration experiment 40 mg of the luciferase-reporter vector and 15 mg of
the b-galactosidase reference plasmid pCMV-bgal were used.
HeLa cells were transfected by lipofection as follows. 5 3 105 cells
were incubated in 60-mm tissue culture plates with 3 ml of OPTI-MEM
medium containing 15 mg of Lipofectin (Life Technologies, Inc.), 5 mg of
luciferase reporter vector, and 1.5 mg of pCMV-bgal vector. After 16 h,
the transfection mixture was replaced by culture medium, where cells
were maintained for 36–48 h.
Luciferase and b-galactosidase activities were measured 15 h after
transfection for all cells except HeLa, according to Pahl et al. (1991) and
Promega published procedures. For HeLa cells those activities were
determined 36–48 h posttransfection. Luciferase activities were nor-
malized for transfection efficiency to the b-galactosidase levels provided
by the cotransfected internal standard vector pCMV-bgal. Reported
data represented the mean from several independent experiments.
Deletion Constructs of the CD36 Promoter Region—An EcoRI-PstI
fragment of the CD36 gene that contains the TATA box and approxi-
mately 2.8 kilobase pairs upstream from it, was obtained from CD36
genomic phage lCh21ACD36.1 (described by Armesilla and Vega
(1994)). This fragment was ligated to a pair of partially complementary
oligonucleotides (GTGTAGGACTTTCCTGCA and AGCTTGCAG-
GAAAGTCCTACACTGCA, derived from the promoter region 111/128
and displaying PstI and HindIII sites when annealed), and to EcoRI-
HindIII-digested vector pUCBM21. Fragment EcoRI-HindIII was
blunt-ended with Klenow and subcloned into the blunt-ended BglII site
of the luciferase reporter vector pGL2-Basic (Promega) to yield the
plasmid p2.8KbCD36-luc, which included 22.8 kilobase pairs to 128 bp
of the CD36 promoter region. Plasmid p2.8KbCD36-luc was used as the
starting material to generate the progressive 59 end deletion constructs
p2.5KbCD36-luc to p0.6KbCD36-luc using the Erase a Base kit (Pro-
mega). Plasmids of the series p2.8KbCD36-luc to p0.6KbCD36-luc con-
tained the CD36 promoter region comprised between nucleotides 2X
and 128. Plasmids p267CD36-luc to p38CD36-luc were generated by
PCR using the DNA isolated from phage lCh21ACD36.1 as template
and pairs of oligonucleotides containing sites for restriction enzymes
KpnI and XhoI. The resulting PCR fragments were ligated to KpnI-
XhoI-digested vector pGL2-Basic. The structure of all of the PCR-
generated constructs was confirmed by DNA sequencing. Plasmids of
the series p267CD36-luc to p38CD36-luc contained the CD36 promoter
region comprised between nucleotides 2X and 143.
Site-directed Mutagenesis—Mutation in the PEBP2 site at position
2103 of the CD36 promoter was performed by polymerase chain reac-
tion. Plasmid p158CD36-luc was used as a template. Primer A (GTT-
GGTACCTCAGTAATGTGCTGTGT) and primer B (GCGAAGCTTTT-
GTTGCCAGAGGAATTGAAAG) were used to generate fragment 1.
Primers C (GCGAAGCTTCACTGGGATCTGACACTGTAG) and D
(GGTCTCGAGGATCAAATGGTATTCTGCAGG) were used to generate
fragment 2. Primers B and C were partially complementary and carried
the point mutations for the PEBP2 site. PCR fragment 1 was digested
with KpnI and HindIII. PCR fragment 2 was digested with HindIII and
XhoI. Both digested fragments were ligated to KpnI-XhoI vector pGL2-
Basic to generate the pCD36–158(m2102/298)-luc plasmid. Nucleotide
sequence of the mutant was confirmed by DNA sequencing.
Nuclear Extracts and EMSA—Nuclear extracts were prepared as
described by Schreiber et al. (1989), with the inclusion of the phospha-
tase inhibitor sodium orthovanadate at 10 mM, the protease inhibitors
aprotinin, leupeptin, and pepstatin at 1 mg/ml, and phenylmethylsulfo-
nyl fluoride at 2 mM.
For EMSA experiments double-stranded oligonucleotides were 32P-
labeled using avian myeloblastosis virus reverse transcriptase. 0.5 ng of
probe at a specific activity of about 108 cpm/mg were incubated for 15
min at 4 °C with 2–6 mg of nuclear extracts in 20 ml containing 28 mM
EDTA, 15 mM KCl, 6 mM MgCl2, 7 mM HEPES (pH 7.9 at 4 °C), 7%
glycerol, 1 mM dithiothreitol, 2.5 mg of poly(dI-dC), and 1 mg of acety-
lated DNase-free bovine serum albumin. For competition assays, unla-
beled oligonucleotides were added to the nuclear extracts at a 50-fold
molar excess 15 min before the addition of the radiolabeled probe. When
required, antibodies were added to the nuclear extracts 15 min prior to
the addition of the radioactive probe. Two ml and 1 ml of the antibodies
a-AML1 (Meyers et al., 1993) and R3034 (kindly provided by Dr. N. A.
Speck) were used, respectively. Binding reactions were electrophoresed
at 15 V/cm on 4–5% polyacrylamide gels in 0.4 3 TBE (45 mM Tris base,
45 mM boric acid, 1 mM EDTA) at 4 °C. Gels were dried and exposed to
Kodak XAR film. The sequence of the oligonucleotides used for EMSA is
shown in the figure legends.
RESULTS
A 158-bp Fragment from the 59 Region of the CD36 Gene
Controls Gene Expression in Monocytic Cell Lines—The in-
volvement of CD36 expressed on monocyte/macrophage cells in
atherosclerosis development and phagocytosis of apoptotic cells
prompted us to investigate the transcriptional regulation of the
CD36 gene in this cell type. As cell models we have used the
widely characterized monocytic cell lines Mono Mac 6, U937,
and THP-1 (Ziegler-Heitbrock et al., 1988; Lu¨bbert et al., 1991).
All of them displayed CD36 on the cell surface as determined
by staining with fluoresceinated CD36-specific antibodies.2 By
contrast, Jurkat, K562, and HeLa cells were used as nonex-
pressing CD36 cell lines, as evidenced by the absence of CD36-
specific cell surface staining and by Northern blot analysis.2
To examine the promoter activity of the 59-flanking region of
the CD36 gene and to identify potential cis-acting regulatory
elements essential for its constitutive transcriptional activity,
a series of deletion fragments of the region 59-upstream from
the TATA box of the CD36 gene (in the range from 22.8
kilobase pairs to 238 bp) was generated and coupled to the
luciferase reporter vector pGL2-Basic. Plasmids were trans-
fected in several cell lines, and the luciferase activity directed
by each construct was measured as described under “Experi-
mental Procedures.”
CD36 deletion promoter constructs yielded between 40- and
80-fold higher luciferase activities than the pGL2-Basic pro-
moterless construct in Mono Mac 6 and U937 cells (Figs. 1, A
and C), while they only reached a maximum of 14 times in
Jurkat and K562 cells (Fig. 1, B and D), demonstrating that 1)
the 59-upstream region of the CD36 gene possesses promoter
activity and 2) the reporter luciferase gene under the control of
the CD36 promoter is more efficiently transcribed in the CD36-
expressing monocytic cell lines Mono Mac 6 and U937 than in
the non-CD36-expressing cell lines Jurkat and K562. In this
regard, the promoter activities of the CD36 constructs in Mono
1 The abbreviations used are: PEBP2/CBF, polyomavirus enhancer-
binding protein 2/core-binding factor; EMSA, electrophoretic mobility
shift assay; PCR, polymerase chain reaction; bp, base pair(s).
2 A. L. Armesilla, D. Calvo, and M. A. Vega, unpublished
observations.
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Mac 6 and U937 cells were higher than or comparable with the
activity directed by vector pGL2-Promoter (Promega) (which
contains the SV40 promoter), while they were significantly
lower in the cell lines Jurkat and K562 (Fig. 1, A–D). Taken
together, these observations indicate that the activity of the
CD36 promoter correlates with the expression levels of CD36
and suggests that the promoter contains regulatory elements
that contribute to the tissue-specific expression of this gene in
monocytic cell lines.
As shown in Fig. 1A, comparable luciferase activities were
obtained after transfection of constructs having 59 ends ranging
from 22.8 kilobase pairs to 2158 bp in Mono Mac 6 cells,
indicating that the region 2158/143 retains most of the pro-
moter activity (Fig. 1A). Data obtained with U937 cells further
supported this finding (Fig. 1C).2 Nevertheless, our experi-
ments did not rule out the possibility that other regions located
upstream from position 2158 may play important positive or
negative regulatory roles, which might have remained hidden
by mutual compensatory effects. A further deletion extending
to 290 bp resulted in a 70% reduction of the basal promoter
activity in both Mono Mac 6 and U937 cells, dropping the
activity to the levels found out in the CD36-negative cell lines
Jurkat and K562 (Fig. 1, A–D). These results point out the
presence of strong positive regulatory elements within the re-
gion 2158/290, which are required for the efficient transcrip-
tion of the CD36 gene in monocytic cell lines. Deletion to 238
bp (a construct that still preserved an intact TATA box) abro-
gated promoter activity, indicating the presence of regulatory
elements in the region 290/238 necessary for the basal tran-
scription of the CD36 gene.
The Region Comprising the Nucleotides 2102/298 Is Re-
quired for Optimal Transcription of the CD36 Gene—A search
within the 2158/290 region for nucleotide sequences corre-
sponding to binding sites for known transcription factors re-
vealed the sequence ACCACA at position 2103, which con-
forms to the core site for the binding of the transcription factors
belonging to the PEBP2/CBF family (Meyers et al., 1993;
Ogawa et al., 1993b), also referred as the AML1 family.
To evaluate the functional significance of the putative
PEBP2 site, the core PEBP2 binding site within the pCD36–
158-luc construct was mutated from ACCACA to AAGCTT
(originating the construct pCD36–158(m2102/298)-luc).
When these constructs were transfected in Mono Mac 6 and
U937 cells, the promoter activity directed by the mutant con-
struct pCD36–158(m2102/298)-luc was 30% of the activity
obtained by the wild type construct pCD36–158-luc (Fig. 2). By
contrast, comparable activities were yielded by both the mu-
tant and wild type constructs in HeLa cells, an observation
consistent with the low levels of PEBP2/CBF factors detected
in this cell line (Fig. 3). In Jurkat cells, the mutant also de-
creased the low promoter activity directed by the wild type
construct. This observation, in agreement with the presence of
PEBP2/CBF factors in this cell line (Figs. 3 and 4), suggests
that the PEBP2/CBF site by itself does not confer the tissue
specificity of the CD36 gene in monocytic cells. Interestingly,
the level of reduction in promoter activity in monocytic cells
when the PEBP2/CBF site was mutated was similar to the
decrease in promoter activity observed when the activity di-
rected by the pCD36–90-luc construct (which does not contain
the PEBP2 site) was compared with the activity yielded by the
pCD36–158-luc construct (which does contain the PEBP2 site)
(Fig. 1, A and C). These results demonstrate the importance of
the region 2102/298 for the constitutive transcription of the
CD36 gene.
Transcription Factors of the PEBP2 Family Bind to the
2102/298 Region—To investigate the trans-acting factors
that account for the promoter activity ascribed to the 2102/298
region, a double-stranded oligonucleotide spanning the 2110/
291 region and comprising the PEBP2 core sequence AC-
CACA, was radiolabeled and used as a probe in EMSA with
FIG. 1. Deletion analysis of CD36 promoter. A panel of CD36 promoter deletion constructs coupled to the reported luciferase gene were
transiently transfected into the cell lines Mono Mac 6, U937, Jurkat, and K562, as described under “Experimental Procedures.” Promoter activity
of each construct was expressed as -fold activity above the background activity conferred by the promoterless control plasmid pGL2-Basic, corrected
for transfection efficiency (Bo¨ttinger et al., 1994). Number enclosed in parenthesis in charts B and D denote the relative luciferase activities yielded
by the pGL2-promoter construct (which contains the SV40 promoter).
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nuclear extracts derived from several cell lines, including the
monocytic cell lines Mono Mac 6, U937, and THP-1 (Fig. 3).
Major low mobility complexes were observed for all of them,
although practically undetectable levels were found in nuclear
extracts from HeLa cells. The specificity of the complexes was
verified by competition with an excess of the unlabeled oligo-
nucleotide.2 The multiplicity, distinct relative mobilities, and
wide cellular distribution of the complexes bound to oligonu-
cleotide 2110/291 was consistent with the EMSA pattern for
transcription factors of the PEPB2/CBF family (Fig. 3) (Meyers
et al., 1993, 1995; Ogawa et al., 1993b; Nuchprayoon et al.,
1994). The dissimilarity between the retardation complexes
detected in the monocytic cell lines analyzed (Figs. 3 and 4A)
may be the result of partial proteolytic degradation of the
nuclear extracts obtained from cell lines MonoMac 6 and U937.
In fact, high levels of protease activity have been reported in
nuclear extracts derived from monocytic cell lines, making
isolation of nuclear extracts without proteolytic degradation
extremely difficult (Galson and Housman, 1988; Pahl et al.
1993). Particularly, susceptibility to proteolytic cleavage of
PEBP2/CBF factors in nuclear extracts from some monocytic
cell lines has been documented (Nuchprayoon et al., 1994).
Moreover, the relative intensities of the complexes derived
from Mono Mac 6 showed significant variations depending on
the preparation and age of the extract and on the numbers of
freezing and thawing processes undergone by the extract.2 For
the above reasons, only the experiments performed with nu-
clear extracts from THP-1 are shown, although similar conclu-
sions were reached when nuclear extracts from Mono Mac 6
and U937 cells were used.2
Binding of radiolabeled oligonucleotide 2110/291 to nuclear
extracts from THP-1 and Jurkat cells gave rise to several
complexes whose formation was completely prevented by a
50-fold excess of the same unlabeled oligonucleotide, demon-
strating their specificity (Fig. 4A). An oligonucleotide contain-
ing a consensus core for the PEBP2/CBF site (designated as
AML1 cons.) and derived from the Moloney virus enhancer
(Wang and Speck, 1992) competed the binding of all complexes
to the oligonucleotide 2110/291, indicating that the sequence
ACCACA was responsible for the appearance of the observed
complexes (Fig. 4A). This observation was confirmed by the
absence of inhibition by a mutant oligonucleotide (2110/291
mut), which spanned the 2110/291 region and contained a
cluster of mutations identical to those generated in the mutant
construct pCD36–158(m2102/298)-luc (Fig. 4A). These data
indicate that the decrease of transcriptional activity in this
mutant is due to the loss of its capability to interact with the
factors bound to the PEBP2/CBF site (nucleotides 2103/298).
To identify the molecular nature of the complexes observed,
nuclear extracts obtained from THP-1 and Jurkat were inde-
pendently incubated with two distinct antibodies specific for
AML1 factors before the addition of the labeled oligonucleotide
2110/291. As shown in Fig. 4B, the a-AML1 antisera, raised
against the N-terminal region of the AML1 a subunit (Meyers
et al., 1993), induced specific supershift in only a fraction of the
complexes (as negative control see last lane showing the bind-
ing of the probe to the antibody). Identical results have been
obtained by several investigators (Meyers et al., 1993; Nu-
chprayoon et al., 1994; Zhang et al., 1994). Moreover, the rabbit
polyclonal antibody R3034 raised against the DNA-binding
domain of AML1, but not a preimmune rabbit serum, pre-
vented the formation of most of the complexes. Given the high
degree of amino acid sequence similarity within the regions
used to generate both the a-AML1 and the R3034 antisera,
between the different members constituting the PEBP2/CBF
family, it is conceivable that both antisera react with several
members of the PEBP2/CBF transcription family (Levanon et
al., 1994). Finally, a similar set of experiments was carried out
using extracts isolated from peripheral blood monocytes (Fig.
5). As expected, PEBP2/CBF transcription factors present in
monocytes bind in vitro to the CD36 promoter, therefore allow-
ing us to extend the conclusions to normal (nontransformed)
monocytes. Altogether, these findings demonstrate that factors
belonging to the PEBP2/CBF family bind to the region 2103/
298 of the CD36 promoter and regulate its functional activity
.
DISCUSSION
In this report we have examined the transcriptional regula-
tion of the CD36 gene in monocytic cell lines. Deletion analysis
has revealed 1) that the CD36 promoter contributes to its
FIG. 2.Mutation of site 2102/298 severely impairs the activity
of the CD36 promoter. CD36 promoter wild type construct pCD36–
158-luc (represented as 158wt) and mutant construct pCD36–
158(m2102/298)-luc (represented as 158mut) were transiently trans-
fected in Mono Mac 6, U937, Jurkat, and HeLa cells. For each cell line
assayed, promoter activities were represented as indicated for Fig. 1.
FIG. 3. Binding of CD36 promoter region 2110/291 to nuclear
extracts from several cell lines. Radiolabeled double-stranded CD36
promoter 2110/291 oligonucleotide, GCAACAAACCACACACTGGG,
was incubated with nuclear extracts from cell lines lines of different
origin (Mono Mac 6, U937, and THP-1, monocytic; JY, B lymphoblas-
toid; Jurkat, T cell leukemia; HeLa, epitheloid carcinoma).
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monocytic-specific expression, and 2) that most of the promoter
activity is contained within the 2158/143 region, which en-
compasses the subregion 2158/290 required for the efficient
transcription of the gene in monocytic cells. We have also
shown that within the above region members of the PEBP2/
CBF family of transcription factors bind to nucleotides 2103/
298. Moreover, mutation of the PEBP2 site severely impaired
the expression of a reporter gene under the control of the CD36
promoter, outlining the significant contribution of the PEBP2/
CBF site to the transcriptional activity of the CD36 gene.
PEBP2/CBF are heterodimeric DNA-binding proteins. They
were initially identified as factors interacting with the poly-
omavirus enhancer core site (Wang and Speck, 1992). They are
constituted by an a subunit, which binds to the DNA consensus
sequence ACCACA (Meyers et al., 1993) and harbors a trans-
activation domain, and a b subunit, which enhances the DNA-
binding affinity of the a subunit through heterodimer forma-
tion (Ogawa et al., 1993a; Wang et al., 1993). While the b
subunit is encoded by a single gene, the a subunits are encoded
by three genes, designated as PEBP2aA, PEBP2aB, and
PEBP2aC in mouse and AML3, AML1, and AML2 in human,
respectively (Bae et al., 1994, 1995; Levanon et al., 1994). The
a subunits share a 128-amino acid region known as the runt
domain, first found (and hence its name) in the Drosophila
melanogaster segmentation gene, runt (Kania et al., 1990; Ka-
goshima et al., 1993). This domain is required for DNA binding
and heterodimerization (Ogawa et al., 1993b). Alternatively
spliced forms for the a subunits (Ogawa et al., 1993b, Bae et al.,
1994, Levanon et al., 1994) and the b subunit (Ogawa et al.
1993a, Wang et al., 1993) have been described. The relevance in
gene regulation of the different protein forms is at present
unknown (Bae et al., 1994).
On the basis of the cellular distribution, one should expect to
find transcripts corresponding to all of the three AML a sub-
units in monocytic cell lines (Levanon et al., 1994). Neverthe-
less, identification of the a subunits, which interact with the
CD36 promoter must await generation of specific reagents for
each subunit.
So far, only a few genes have been shown to be regulated by
the PEBP2/CBF transcription factors. Gene expression of the
myeloid genes encoding murine neutrophil elastase, myeloper-
oxidase (Suzow and Friedman, 1993; Nuchprayoon et al., 1994),
and human colony-stimulating factor receptor (Zhang et al.,
1994) is controlled by PEBP2/CBF transcription factors. Func-
tional sites for PEBP2/CBF factors have been also described in
the enhancers of T cell receptor genes (Gottschalk and Leiden,
FIG. 4. CD36 promoter contains a
PEBP2/CBF site at region 2103/298.
A, radiolabeled double-stranded CD36
promoter 2110/291 oligonucleotide was
incubated with nuclear extracts from cell
lines THP-1 and Jurkat. Prior to adding
the radiolabeled oligonucleotide, nuclear
extracts were incubated with a 50-fold
molar excess of the following cold double-
stranded oligonucleotides: 2110/291, to
demonstrate specificity of complexes;
2110/291 mut (GCAACAAAAGCT-
TCACTGGG), to assay the effect of posi-
tions 2102/298 in the binding; and AML1
cons. (GGATATCTGTGGTAAGCA), an
oligonucletide containing a PEBP2/CBF
consensus site from the Moloney murine
leukemia virus enhancer, to assay the
molecular nature of the complexes bound
to oligonucleotide 2110/291. 2, no inhib-
itor added. B, nuclear extracts from cell
lines THP-1 and Jurkat were incubated
with radiolabeled double-stranded oligo-
nucleotide 2110/291, without (2) or with
a prior incubation with a 50-fold molar
excess of cold oligonucleotide 2110/291,
rabbit preimmune sera (PI), or AML1-
specific antisera a-AML1 or R3034. The
last lane shows the effect of the antisera
a-AML1 on the labeled double-stranded
oligonucleotide 2110/291 in the absence
of nuclear extract.
FIG. 5.Nuclear extracts from peripheral blood monocytes con-
tain PEBP2/CBF factors that bind to the CD36 promoter PEBP2/
CBF site. Radiolabeled double-stranded CD36 promoter 2110/291
oligonucleotide was incubated with nuclear extracts from THP-1 cells
and from peripheral blood monocytes. Prior to adding the radiolabeled
oligonucleotide, nuclear extracts from monocytes were incubated with a
50-fold molar excess of the cold double-stranded oligonucleotides 2110/
291, 2110/291 mut, and AML1 cons. (see Fig. 4 legend for details) or
with rabbit preimmune sera (PI) or AML1-specific antisera R3034. 2,
no inhibitor added.
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1990; Redondo et al., 1992) and in the enhancers of murine
leukemia viruses (Wang and Speck, 1992).
Like the murine myeloid genes neutrophil elastase, my-
eloperoxidase (Nuchprayoon et al., 1994), and the T cell recep-
tor a enhancer (Giese et al., 1995), trans-activation experi-
ments carried out in HeLa cells with vector pEF-BOSaB1
(which drives the expression of the aB chain) did not enhance
the activity of the pCD36–158-luc construct,2 suggesting the
requirement of other factors for the transcriptional activation
mediated by PEBP2/CBF. In this respect, reconstitution of the
T cell receptor a enhancer activity in nonlymphoid cells re-
quired the assembly of a stereospecific complex constituted by
the transcription factors PEBP2/CBF, Ets-1, and the lymphoid-
specific high-mobility group protein LEF-1 (Giese et al., 1995).
That the mutation of the PEBP2 site abolished most of the
transcriptional activity does not imply that other sites for tran-
scription factors might not be required for efficient transcrip-
tion of the CD36 gene. Transcription factors Ets-1, Ets-2 (Wot-
ton et al., 1994), and Myb (Herna´ndez-Munain and Krangel,
1994, 1995) are known to synergize with PEBP2/CBF factors.
Meyer et al. (1995), on the basis of the functional studies of
PEBP2/CBF sites in several promoters, have outlined the con-
clusion that the PEBP2/CBF factors are necessary but not
sufficient for tissue-specific activity. Our data on the PEBP2/
CBF site in the CD36 promoter support this statement.
The human AML1 gene is involved in translocations t(8;
21)(q22;q22) and t(3;21) (q26,q22) (reviewed by Nucifora and
Rowley (1995)) and accounts for 12% of all forms of acute
myeloid leukemia (Miyoshi et al., 1993). In addition, the human
PEBP2/CBF b gene undergoes an inversion (inv(16)(p13q22)),
also associated with a particular subtype of acute myeloid
leukemia (Liu et al., 1993). The short transcript form of AML1
(designated as AML1a), which lacks the transactivation do-
main, as well as the fusion proteins resulting as a consequence
of the translocations dominantly suppress transcriptional acti-
vation by presumably interfering with binding of transactivat-
ing PEBP2/CBF forms (Meyers et al., 1995). Through this
mechanism the PEBP2/CBF forms lacking transactivation ca-
pacity inhibit myeloid differentiation and may cause leukemia
(Tanaka et al., 1995). All of these studies highlight the impor-
tance of the AML1 gene in myeloid cell growth and/or differen-
tiation, and strengthen its proposed role in the regulation of
CD36 gene expression in monocytic cell lines.
Little information is available on the factors and molecular
events that regulate the expression and functional activity of
the PEBP2/CBF genes. Dr. Ito and co-workers (Lu et al., 1995)
have recently discovered that the b subunit of PEBP2/CBF is
mainly found in the cytoplasm, from where it translocates to
the nucleus and binds to the a chain, thus increasing binding
affinity of the a subunit for the DNA. Molecular events that
dictate such a unique regulatory mechansim are so far un-
known, but they are likely to be crucial in regulating the
transcriptional activity of the PEBP2 transcription factors, and
the genes under their control. It would therefore be rational to
investigate whether changes in the expression and in the tran-
scriptional activity of PEBP2 factors occur under conditions
that modulate the RNA expression levels of CD36, such as
interaction of monocytes with E-selectin, interleukin-4, lipopo-
lysaccharide, and g-interferon (Huh et al., 1995).
Interestingly, the high levels of CD36 expression found in
immature erythrocytes (Edelman et al., 1986) may be a conse-
quence of the expression of PEBP2/CBF aB chain detected in
this type of cells (Satake et al., 1995). Nevertheless, the expres-
sion of CD36 in a variety of different tissues makes conceivable
the existence of distinct regulatory mechanisms on each tissue
type. In this respect, expression of CD36 in murine B cells
(although so far not detected in human B cells) has been shown
to be dependent on the transcription factor Oct-2 (Ko¨nig et al.,
1995), a factor not found in all cell types where CD36 is
expressed.
We are currently analyzing the transcription factors govern-
ing the basal promoter activity found downstream from posi-
tion 290. Preliminary experiments indicate that a Sp1 site
close to the TATA box could possibly account for this activity.
The characterization of the CD36 gene promoter provided in
this report establishes the molecular basis to further dissect
the promoter in activating conditions, such as those existing in
the microenvironments where monocytes are found when par-
ticipating in foam cell formation and clearance of apoptotic
cells.
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